Holen Sie sich die Stockscreener-App
0.134
80.66%
-0.559
Handel nachbörslich:
.13
-0.004
-2.99%
Schlusskurs vom Vortag:
$0.693
Offen:
$0.1615
24-Stunden-Volumen:
9.72M
Relative Volume:
39.28
Marktkapitalisierung:
$12.95M
Einnahmen:
$19.91M
Nettoeinkommen (Verlust:
$-127.11M
KGV:
-0.0159
EPS:
-8.428
Netto-Cashflow:
$-132.44M
1W Leistung:
-83.04%
1M Leistung:
-78.46%
6M Leistung:
-96.43%
1J Leistung:
-97.45%
1-Tages-Spanne:
$0.13
$0.1767
1-Wochen-Bereich:
$0.13
$0.80
52-Wochen-Spanne:
$0.13
$8.95
Affimed N V Stock (AFMD) Company Profile
Vergleichen Sie AFMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.134 | 12.95M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-10-10 | Herabstufung | Stifel | Buy → Hold |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-10-21 | Eingeleitet | Truist | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2018-08-28 | Hochstufung | Jefferies | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2016-08-12 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-05-19 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2015-12-10 | Eingeleitet | Laidlaw | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-09-09 | Eingeleitet | Jefferies | Hold |
| 2015-08-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-06-22 | Bestätigt | Jefferies | Buy |
Alle ansehen
Affimed N V Aktie (AFMD) Neueste Nachrichten
AFMD Stock Downgraded as Wells Fargo Slashes Price Target | AFMD - GuruFocus
Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize
Affimed (AFMD) Faces Downgrade Amid Insolvency Proceedings | AFM - GuruFocus
Wells Fargo Downgrades Affimed (AFMD) with New Price Target | AF - GuruFocus
Affimed downgraded to Equal Weight at Wells after insolvency filing - TipRanks
Wells Fargo Downgrades Affimed to Equalweight From Overweight; Shares Plunge - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Affimed (AFMD) Files for Insolvency Amid Financial Challenges - GuruFocus
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Affimed (AFMD) Seeks Insolvency Proceedings Amid Financial Strug - GuruFocus
Affimed (AFMD) Resumes Trading, Offering Market Opportunities | - GuruFocus
Affimed shares crash after filing for the opening of insolvency proceedings - MSN
Affimed Announces Filing for the Opening of Insolvency Proceedin - GuruFocus
Affimed Shares Down, Halted in Premarket on Bankruptcy Application - MarketWatch
Affimed Files for Insolvency Amid Financial Challenges - TipRanks
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Leerink cuts Affimed stock target to $0.39, downgrades rating By Investing.com - Investing.com Nigeria
Affimed Announces Filing for the Opening of Insolvency Proceedings - GlobeNewswire
This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga
AFMD: Leerink Partners Downgrades Affimed with New Price Target - GuruFocus
Affimed (AFMD) Downgraded as Funding Prospects Dim | AFMD Stock News - GuruFocus
Leerink Downgrades Affimed to Market Perform From Outperform - marketscreener.com
Affimed (NASDAQ:AFMD) Now Covered by StockNews.com - Defense World
Affimed N.V.: Q1 Earnings Snapshot - Barchart.com
Affimed Delays Filing of 2024 Yearly Report - TipRanks
Affimed Shows Higher Exposure of AFM24 is Associated with Signif - GuruFocus
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting | AFMD Stock News - GuruFocus
Affimed Shows Higher Exposure of AFM24 is Associated with - GlobeNewswire
Affimed N.V. Reports Positive Findings on AFM24's Exposure-Outcome Analysis in Refractory Non-Small Cell Lung Cancer Patients - Nasdaq
Breakthrough: AFM24 Cancer Drug Achieves 33% Response Rate in Lung Cancer with New Dosing Strategy - Stock Titan
Affimed (NASDAQ:AFMD) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com - Defense World
Affimed Announces Acceptance of Three Abstracts for Presentation - GuruFocus
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting | AFMD Stock News - GuruFocus
Affimed N.V. Announces Accepted Abstracts for Oral and Poster Presentations at ASCO 2025 Annual Meeting - Nasdaq
Affimed Announces Acceptance of Three Abstracts for - GlobeNewswire
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting - TradingView
Affimed Secures Coveted Oral Presentation Slot at ASCO 2025: Phase 2 Lymphoma and Lung Cancer Data - Stock Titan
Affimed faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode - NewsBreak: Local News & Alerts
Affimed Faces Nasdaq Delisting Risk Due to Share Price - TipRanks
Affimed faces Nasdaq delisting over share price rule - Investing.com Australia
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Due to Low Share Price | AFMD Stock News - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Over Share Price - GuruFocus
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | AFMD Stock News - GuruFocus
Affimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Nasdaq
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Affimed Gets 180-Day Nasdaq Grace Period After Stock Falls Below $1, Extension Possible - Stock Titan
Affimed N.V. Receives EUR 2.4 Million Research Grant from German Government to Fund Trispecific Abs - marketscreener.com
Finanzdaten der Affimed N V-Aktie (AFMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):